Rebecca Jordan, MD
Neurology · Sacramento, CANPI 1649243528
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.3% of the total across 764 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations.
Across 764 payments — averaging $26.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$2K
- Livanova USA, Inc.$2K
- UCB, Inc.$2K
- Lilly USA, LLC$808
- Neurocrine Biosciences, Inc.$790
- plus $10K from 47 others
Across 205 payments — averaging $4658.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$266K
- Amgen$239K
- AbbVie$147K
- GSK$127K
- Chiesi USA, Inc.$88K
- Eli Lilly$30K
- plus $57K from 3 others
What the payments were for
- Travel & lodging$1,7739%
- Food & beverage$18,29890%
- Education$2011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,273 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 190 | $282,040 |
| IngrezzaValbenazine Tosylate | 27 | $235,459 |
| Nurtec OdtRimegepant Sulfate | 148 | $195,925 |
| QuliptaAtogepant | 96 | $109,142 |
| NuplazidPimavanserin Tartrate | 20 | $96,437 |
| AptiomEslicarbazepine Acetate | 54 | $89,133 |
| Emgality PenGalcanezumab-Gnlm | 71 | $56,087 |
| RexultiBrexpiprazole | 29 | $38,529 |
| RybelsusSemaglutide | 27 | $37,116 |
| GocovriAmantadine Hcl | 11 | $26,186 |
| RytaryCarbidopa/Levodopa | 26 | $23,585 |
| NourianzIstradefylline | 11 | $20,509 |
| BriviactBrivaracetam | 11 | $16,125 |
| ElyxybCelecoxib | 15 | $12,849 |
| JardianceEmpagliflozin | 13 | $11,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $1,999 | $391,182286 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $790 | $235,45927 claims |
| PfizerNurtec Odt, Eliquis | $672 | $207,128159 claims |
| Acadia Pharmaceuticals IncNuplazid | $43 | $96,43720 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $333 | $89,13354 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $248 | $38,52929 claims |
| Novo NordiskRybelsus | $650 | $37,11627 claims |
| MDD US Operations, LLCGocovri | $444 | $26,18611 claims |
| Amneal Pharmaceuticals LLCRytary | $294 | $23,58526 claims |
| Scilex Pharmaceuticals Inc.Elyxyb, Ztlido | $378 | $23,32543 claims |
| Kyowa Kirin, Inc.Nourianz | $70 | $20,50911 claims |
| UCB, Inc.Briviact | $1,779 | $16,12511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.
Other neurology in Sacramento
- Lin ZhangSacramento$328K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.